Chiesi acquires ex-US Raxone marketing rig...Chiesi Farmaceutici has licenced commercialiation rights for LHON treatment Raxone (idebenone) from Santhera Pharmaceuticals for CHF50m (€44m) in cash plus sales milestones. more ➔
EU ministers set to exclude CRISPR crops... EU agriculture ministers want to exclude crops created by targeted mutation methods from EU GMO legislation. more ➔
Evotec acquires CDMO Just Biotherapeutics... Evotec SE is set to acquire biologics manufacturing specialist Just Biotherapeutics, Inc in a deal that could amount up to $90m. more ➔
AI improves protein manufacture Researchers at German regulatory authority Paul-Ehrlich Institute (PEI) have patented a method to accurately forecast biotech-based protein synthesis in host cells. more ➔
DNA Script raises US$38.5m in Series B rou...In an oversubscribed Series B round led by LSP, Paris-based DNA Script raised US$38.5. Bpifrance and existing investors Illumina Ventures, M. Ventures, Sofinnova Partners, Kurma Partners and Idinvest … more ➔
Hedging successAlthough the Swiss biotech sector continues to grow and the annual Swiss Biotech Day is as sought-after as never before, panelists and attendees remain cautious with their predictions. A reoccurring … more ➔
Dutch-Italian team improves retinal gene t...Researchers from Universities Nijmegen and Naples have presented a retinal AAV-based gene therapy delivery system that can express huge genetic elements by assembling protein fragments from several vectors. … more ➔
Mobidiag secures €25m loan from EIBMolecular diagnostics company Mobidiag has received an EIB loan to accelerate the development and commercialisation of its in vitro diagnostic solutions for infectious diseases. more ➔
Philogen SpA raises €62m to push registr...Privately financed Italian antibody-cytokine fusion protein specialist Philogen SpA has secured €62m from private investors including the Neri and Dompé families to push registration of two … more ➔
Halt of Polyphor trial shrinks company val...Roche had a nose for success when the pharma giant ended the CHF500m deal with Polyphor in November 2015. Now, the antibiotics maker stopped a Phase III trial of its lead murepavadin (Pol7080). more ➔
